| Theme | Designated intractable kidney diseases：The control in non-dialysis CKD and renal replacement therapy | |
|---|---|---|
| Title | IgA nephropathy and Henoch -- Schönlein purpura nephritis | |
| Publish Date | 2016/04 | |
| Author | Ritsuko Katafuchi | Kidney Unit, National Fukuoka Higashi Medical Center |
| [ Summary ] | IgA nephropathy (IgAN) patients who meet either of the following criteria may be considered to have an intractable disease. The first is red indications on heat maps of CKD urinary protein (UP) levels of 0.5 g/gCr or higher. Second, is histological grade III or IV prognoses. Patients with intractable disease in both IgAN and Henoch-Schönlein purpura nephritis (HSPN) are at elevated risk to progress to end-stage renal failure. Immunosuppressants are used in such patients. Tonsillectomy is another strategy for mitigating this condition. Although Japanese guidelines for IgAN were recently established, there are no guidelines for patients with HSPN. Allograft recipients originally diagnosed with IgAN or HSPN must be monitored for recurrence. |
|